NEW YORK (GenomeWeb News) - Strategic Diagnostics said today that its board of directors has approved a program to repurchase up to $3 million of the company's outstanding shares of common stock over the next 12 months.
 
"We believe that our stock price does not reflect our belief in the long term value of Strategic Diagnostics,” Francis DiNuzzo, president and CEO, said in a statement. “A repurchase program will benefit SDI's shareholders and demonstrates our board's and management team's confidence in our business.”
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.